[1] [1] ROMINE J L, LAURENT D R, LEET J E,et al. Inhibitors of HCV NS5A: from iminothiazolidinones to symmetrical stilbenes [J].ACS Med Chem Lett, 2011,2(3): 224-229.

[2] [2] LEE C, MA H, HANG J Q,et al. The hepatitis C virus NS5A inhibitor (BMS-790052) alters the subcellular localization of the NS5A non-structural viral protein [J].Virology, 2011,414(1): 10-18.

[3] [3] POL S, GHALIB R H, RUSTGI V K,et al. Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebocontrolled, dose-finding, phase 2a trial [J].Lancet Infect Dis, 2012,12(9): 671-677.

[5] [5] GAO M, NETTLES R E, BELEMA M,et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect [J].Nature, 2010,465(7294): 96-100.

[6] [6] BELEMA M, NGUYEN V N, BACHAND C,et al. Hepatitis C virus NS5A replication complex inhibitors: the discovery of daclatasvir [J].J Med Chem, 2014,57(5): 2013-2032.

[7] [7] LIM P J, GALLAY P A,et al. Hepatitis C NS5A protein: two drug targets within the same protein with different mechanisms of resistance [J].Curr Opin Virol, 2014,8: 30-37.

[8] [8] WANG C, VALERAL, L JIA,et al.In vitroactivity of daclatasvir on hepatitis C virus genotype 3 NS5A [J].Antimicrob Agents Chemother, 2013,57(1): 611-613.

[9] [9] WANG C, JIA L, O’BOYLE D R,et al. Comparison of daclatasvir resistance barriers on NS5A from hepatitis C virus genotypes 1 to 6: implications for cross-genotype activity [J].Antimicrob Agents Chemothe, 2014,58(9): 5155-5163.

[10] [10] WANG C F, L JIA, HUANG H C,et al.In vitroactivity of BMS-790052 on hepatitis C virus genotype 4 NS5A [J].Antimicrob Agents Chemother, 2012,56(3): 1588-1590.

[11] [11] SHAWN K, PENG GENG, MICHAEL J S,et al. Process for synthesizing compounds useful for treating hepatitis C: US, 07728027B2 [P]. 2010-06-01.

[12] [12] YU Y, ZHANG Y J, CAI M Z. Structure-controlled synthesis of novel soluble and thermally stable poly (aryl ether nitrile ether ketone ketone)/poly (aryl ether nitrile ether ketone biphenyl ketone) copolymers by electrophilic polycondensation[J].Polym Adv Technol, 2011,22(12): 2543-2549.

[13] [13] SMART L A. Synthesis and biological activity of a 2-bromoethylamine (mustard) derivative of hemicholinium-3 and hemicholinium-15 [J].J Med Chem, 1983,26(1): 104-107.

[14] [14] RANA A, BHUSHAN M, SUBHASH G,et al. Integrated multi-step continuous flow synthesis of daclatasvir without intermediate purification and solvent exchange [J].Reaction Chem Eengineer, 2020,5(11): 2109-2114.

[15] [15] MOORE T O, PARADOWSKI M, WARD S E. An atomefficient and convergent approach to the preparation of NS5A inhibitors by C-H Activation [J].Org Biomol Chem, 2016,14(12): 3307-3313.

[17] [17] MAHAJAN B, DNYANESHWAR A, MANDEEP P,et al. Elements-continuous-flow platform for coupling reactions and anti-viral daclatasvir API synthesis [J].Synthesis, 2022,56(4): 657-667.